Optimizing Endocrinology Prior Authorizations for Naviguard Utilization Management

Navigating prior authorizations in endocrinology, especially with complex utilization management programs like Naviguard, demands precision and efficiency. Klivira streamlines the entire workflow, from submission to approval.

Revenue cycle leaders and prior authorization teams in endocrinology face unique challenges, including high-volume drug categories like GLP-1s and devices such as CGMs and insulin pumps. When interacting with UnitedHealthcare's Naviguard program, these complexities are amplified, requiring meticulous documentation and adherence to specific payer criteria.

The Intersection of Endocrinology and Naviguard UM

Endocrinology practices manage a significant volume of prior authorizations for high-cost medications and devices critical for diabetes and other endocrine conditions. These frequently trigger utilization management (UM) reviews by UHG entities like Naviguard. Successfully navigating these reviews requires robust data submission and adherence to specific, often evolving, payer criteria for coverage.

Key Prior Authorization Triggers in Endocrinology

GLP-1 Receptor Agonists & Dual GIP/GLP-1s (e.g., semaglutide, tirzepatide) for Type 2 Diabetes and obesity indications.
Continuous Glucose Monitors (CGMs) and Insulin Pumps (e.g., Dexcom, FreeStyle Libre, Tandem, Omnipod).
Growth Hormone Therapy, including somatropin biosimilars and lonapegsomatropin.
SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin) for Type 2 Diabetes, heart failure, and chronic kidney disease.
Specific thyroid procedures and radioactive iodine treatments.
Insulin analogs, particularly when step therapy or biosimilar substitution is required.

Meeting Naviguard's Documentation Requirements with Precision

UnitedHealthcare's Naviguard UM processes often align with established clinical guidelines such as the ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines. For endocrinology PAs, this translates to specific data points: A1c levels, BMI with comorbidities, prior medication trials, ejection fraction for heart failure, and eGFR thresholds for kidney disease. Klivira ensures these critical data elements are systematically captured and presented.

Klivira's Intelligent Automation for Endocrinology Naviguard Workflows

Klivira's platform integrates directly with your EMR, leveraging standards like SMART on FHIR to extract necessary clinical data. Our rules engine applies ADA/AACE-guideline-aware logic, handles complex step-therapy requirements, and manages indication-specific routing for GLP-1s, ensuring submissions meet Naviguard's stringent criteria. This tailored approach reduces manual effort and improves submission accuracy.

Streamlining Payer Touchpoints and Reducing Denials

Klivira automates the submission process for endocrinology PAs via X12 278 transactions, ePA portals, and other digital channels, minimizing manual data entry and potential errors. This proactive approach helps address common denial reasons from UHG plans, such as GLP-1 obesity indication coverage gaps, non-compliance with step therapy, and biosimilar substitution requirements, improving first-pass approval rates.

Continuous Monitoring and Re-authorization Management

Many endocrinology treatments, particularly devices like CGMs and insulin pumps, require periodic re-authorization. Klivira supports these ongoing cycles by tracking re-authorization timelines and facilitating the collection of necessary adherence and clinical documentation. This ensures timely submissions to Naviguard, preventing lapses in patient care due to administrative delays.

Frequently asked questions

How does Klivira handle the high volume of GLP-1 prior authorizations for Naviguard?

Klivira's platform automates data extraction from the EMR and applies payer-specific rules, including step-therapy and indication-based criteria, to efficiently process high volumes of GLP-1 PAs for Naviguard and other UHG plans. This reduces manual burden and accelerates submission by ensuring all required clinical documentation is present.

What clinical guidelines does Klivira use for endocrinology PAs submitted to Naviguard?

Klivira's rules engine incorporates logic aligned with dominant clinical guidelines such as the ADA Standards of Care and AACE Clinical Practice Guidelines. This ensures that submitted documentation for endocrinology prior authorizations meets the evidence-based criteria often referenced by Naviguard's utilization management policies.

Can Klivira help with re-authorizations for CGMs and insulin pumps with UHC Naviguard?

Yes, Klivira supports the full lifecycle of device prior authorizations, including re-authorization workflows for CGMs and insulin pumps. The platform tracks re-authorization timelines and helps gather necessary adherence and clinical documentation for timely submission to Naviguard, minimizing interruptions to patient therapy.

How does Klivira address common denial reasons from Naviguard for endocrinology medications?

Klivira proactively addresses common denial reasons by ensuring comprehensive documentation, verifying step-therapy compliance, and checking for payer-specific coverage criteria (e.g., BMI for obesity medications, insulin-requiring status for CGM). This minimizes denials related to coverage gaps or insufficient clinical data for UHG plans.

Does Klivira integrate with our existing EMR for endocrinology Naviguard submissions?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to seamlessly extract patient data. This ensures that all necessary clinical information for endocrinology prior authorizations is accurately captured and submitted to Naviguard without manual re-entry, improving efficiency and data integrity.